PTC Therapeutics partners with Novartis for its PTC518 Huntington’s program in a deal valued up to $2.9 billion, including milestones and royalties.
PTC Therapeutics Inks Licensing Pact With Novartis Worth Up To ~$3 Billion For Huntington’s Program
Where Today's News Shapes Tomorrow
